Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.79 USD | -1.53% | -12.67% | -15.23% |
02/05 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
02/05 | Earnings Flash (AXGN) AXOGEN Posts Q1 Revenue $41.4M, vs. Street Est of $42.1M | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- Low profitability weakens the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.23% | 253M | C | ||
+7.84% | 218B | B | ||
+7.35% | 184B | B- | ||
+13.04% | 135B | B- | ||
+26.03% | 107B | A- | ||
-1.33% | 62.38B | A- | ||
+11.80% | 51.37B | B+ | ||
+4.81% | 50.9B | B+ | ||
+0.30% | 40.87B | A | ||
+2.78% | 36.28B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AXGN Stock
- Ratings AxoGen, Inc.